Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.

Read this article at

ScienceOpenPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Although previous clinical study revealed that bortezomib combined with dexamethasone had improved the outcomes of relapsed or refractory multiple myeloma (RRMM), the optimal dose combinations of bortezomib and dexamethasone remain unknown. This trial aimed to observe the efficacy and safety of different dose combinations of bortezomib and dexamethasone in the treatment of RRMM patients in China.

      Related collections

      Author and article information

      Affiliations
      [1 ] Department of Hematology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
      Journal
      Chin. Med. J.
      Chinese medical journal
      0366-6999
      0366-6999
      Oct 2011
      : 124
      : 19
      22040537

      Comments

      Comment on this article